PMID- 22385316
OWN - NLM
STAT- MEDLINE
DCOM- 20130507
LR  - 20181201
IS  - 1744-7593 (Electronic)
IS  - 1742-5247 (Linking)
VI  - 9
IP  - 4
DP  - 2012 Apr
TI  - Drug delivery in multiple indication (multipurpose) prevention technologies: 
      systems to prevent HIV-1 transmission and unintended pregnancies or HSV-2 
      transmission.
PG  - 417-27
LID - 10.1517/17425247.2012.668183 [doi]
AB  - INTRODUCTION: The development of multiple indication (multipurpose) prevention 
      technologies (MIPTs) is driven by overlapping relationships in the area of female 
      reproductive health. AREAS COVERED: In this review, the basis for MIPTs is 
      detailed. The current state of the field for the use of drug delivery in novel 
      MIPTs is covered. Of particular interest is the application of intravaginal rings 
      (IVRs) for the delivery of two drugs simultaneously, to prevent one STI and 
      pregnancy, or two STIs. IVRs are currently available commercially for 
      contraception and have been developed for release of microbicides to prevent 
      sexual transmission of HIV-1. Novel IVRs capable of releasing relatively large 
      amounts of drugs such as tenofovir are discussed, along with those that contain 
      independent delivery elements, such as pods, that can be used to release drugs at 
      independent rates. The vaginal administration of macromolecules (antibodies and 
      vaccines) is also reviewed in the context of MIPTs. EXPERT OPINION: The field of 
      MIPTs remains one of potential. There is yet to be a proven microbicide effective 
      at preventing sexual transmission of HIV-1. Development of MIPTs in the near term 
      will proceed under the assumption that one or more antiretroviral (ARV) drugs 
      will eventually be proven successful. IVRs have already demonstrated success in 
      the area of contraception. Prevention of sexual transmission of HIV-1 and herpes 
      simplex virus-2 (HSV-2) (or suppression of recurrence) remains an attractive MIPT 
      target. In the long term, development of MIPTs will require validation of 
      surrogate end points, particularly for prevention of HIV-1 transmission.
FAU - Friend, David R
AU  - Friend DR
AD  - Eastern Virginia Medical School, CONRAD, Department of Obstetrics and Gynecology, 
      1911 North Fort Myer Drive, Suite 900, Arlington, VA 22209, USA. 
      dfriend@conrad.org
LA  - eng
PT  - Journal Article
PT  - Research Support, U.S. Gov't, Non-P.H.S.
PT  - Review
DEP - 20120302
PL  - England
TA  - Expert Opin Drug Deliv
JT  - Expert opinion on drug delivery
JID - 101228421
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Antiviral Agents)
RN  - 0 (Organophosphonates)
RN  - 99YXE507IL (Tenofovir)
RN  - JAC85A2161 (Adenine)
SB  - IM
MH  - Adenine/administration & dosage/analogs & derivatives
MH  - Administration, Intravaginal
MH  - Anti-Infective Agents/administration & dosage
MH  - Antiviral Agents/*administration & dosage
MH  - Biopharmaceutics/methods
MH  - Contraception/methods
MH  - Disease Transmission, Infectious/*prevention & control
MH  - Drug Delivery Systems/*methods
MH  - Female
MH  - HIV Infections/drug therapy/prevention & control/*transmission
MH  - HIV-1/drug effects
MH  - Herpes Genitalis/drug therapy/prevention & control/*transmission
MH  - Herpesvirus 2, Human/drug effects
MH  - Humans
MH  - Organophosphonates/administration & dosage
MH  - Pregnancy
MH  - Pregnancy Complications, Infectious/*prevention & control
MH  - Pregnancy, Unplanned
MH  - Tenofovir
EDAT- 2012/03/06 06:00
MHDA- 2013/05/08 06:00
CRDT- 2012/03/06 06:00
PHST- 2012/03/06 06:00 [entrez]
PHST- 2012/03/06 06:00 [pubmed]
PHST- 2013/05/08 06:00 [medline]
AID - 10.1517/17425247.2012.668183 [doi]
PST - ppublish
SO  - Expert Opin Drug Deliv. 2012 Apr;9(4):417-27. doi: 10.1517/17425247.2012.668183. 
      Epub 2012 Mar 2.